Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study

Documenti analoghi

• Phase II Evaluation of Neoadjuvant Chemotherapy and Debulking Followed by Intraperitoneal Chemotherapy in Women with Stage III and IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: Southwest Oncology Group Study S0009
  di: Tiersten, Amy D., et al.
  Pubblicazione: (2009)
• SOUTHWEST ONCOLOGY GROUP TRIAL S9912: INTRAPERITONEAL CISPLATIN AND PACLITAXEL PLUS INTRAVENOUS PACLITAXEL AND PEGYLATED LIPOSOMAL DOXORUBICIN AS PRIMARY CHEMOTHERAPY OF SMALL-VOLUME RESIDUAL STAGE III OVARIAN CANCER
  di: Smith, Harriet O., et al.
  Pubblicazione: (2009)
• Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
  di: Markman, Maurie
  Pubblicazione: (2009)
• IMPACT ON SURVIVAL OF 12 VERSUS 3 MONTHLY CYCLES OF PACLITAXEL (175 MG/M(2)) ADMINISTERED TO PATIENTS WITH ADVANCED OVARIAN CANCER WHO ATTAINED A COMPLETE RESPONSE TO PRIMARY PLATINUM-PACLITAXEL: FOLLOW-UP OF A SOUTHWEST ONCOLOGY GROUP AND GYNECOLOGIC ONCOLOGY GROUP PHASE 3 TRIAL
  di: Markman, Maurie, et al.
  Pubblicazione: (2009)
• Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
  di: Markman, Maurie
  Pubblicazione: (2016)